Originally approved for type 2 diabetes and later for obesity treatment, GLP-1 and other incretin-based therapies have rapidly gained traction in both clinical and consumer spaces
doi: 10.1016/j.npep.2022.102250 [DOI] [PubMed] [Google Scholar] 51.Sindhu U, Sharma A, Zawar I, Punia V
- Katie Hoehn, RD, CSSD, CSCS Sports Performance Dietitian supporting weight-loss clients, including individuals using GLP-1 medications
Benjamin Krasne, M.D
In fact, lower IRRs were observed during both the initial (012 months) and late (1324 months) exposed periods compared with pretreatment, a pattern also seen for SGLT-2 and DPP-4 inhibitors, possibly reflecting increased healthcare contact or a healthier lifestyle during treatment
Moreover, liraglutide was reported to reduce the abnormal proliferation of hyperglycaemia-induced vascular smooth muscle cells by inhibiting the PI3K/AKT and ERK 1/2 signaling pathways (21)